The HNF4A Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population in which the HNF4A gene has been disrupted to create a loss-of-function model in a human gastric epithelial background. This heterogeneous knockout pool is generated by transient introduction of CRISPR components, resulting in a diverse array of genetic modifications across the cell population while retaining the inherent genomic variability of the parental line. The polyclonal format enables robust phenotypic screening and functional analyses without clonal selection pressure, making it particularly suitable for studies where population-level responses to HNF4A ablation are of interest, such as in tumor biology and metabolic research.
The AGS host cell line is a widely utilized model of gastric adenocarcinoma, originally derived from the tumor tissue of a 54-year-old Caucasian female. AGS cells display adherent growth properties and retain characteristics of gastric epithelial differentiation, including the formation of junctional complexes and the expression of certain metabolic enzymes. Their extensive characterization in cancer biology research, including studies on proliferation, migration, and drug response, positions them as a relevant platform for investigating the tumor-suppressive or oncogenic roles of HNF4A in the context of gastric mucosa. The line is permissive to genetic manipulation and standard transfection techniques, facilitating reproducible knockout generation.
HNF4A encodes a master transcription factor that binds direct repeat 1 (DR1) DNA elements to orchestrate gene networks essential for hepatocyte differentiation, metabolic homeostasis, and epithelial barrier integrity. Its activity is tightly controlled by upstream regulators such as HNF1A, FOXA2, CREB, glucocorticoids, and insulin, as well as by negative post-transcriptional regulation via miR-24 and miR-34a. Upon activation, HNF4A directly promotes the expression of downstream targets including APOB, APOA1, CYP3A4, SLC2A2, TTR, and the tight junction proteins CLDN1 and OCLN. HNF4A also engages in cooperative interactions with co-activators and partner transcription factors like PPARA, RXRA, CEBPA, CREBBP, and SMAD2/3, integrating signals from metabolic, developmental, and stress pathways. This positions HNF4A as a central node in glycolysis/gluconeogenesis, MODY, bile acid biosynthesis, fatty acid metabolism, Wnt signaling, and cell adhesion molecule pathways.
In the AGS gastric carcinoma milieu, targeted disruption of HNF4A is predicted to derepress oncogenic traits. Loss of HNF4A function leads to diminished expression of tight junction constituents CLDN1 and OCLN, compromising epithelial barrier integrity and potentially fostering a pro-invasive phenotype. Concomitantly, downregulation of metabolic targets like SLC2A2 (GLUT2), APOB, and CYP3A4 reprograms glucose and lipid metabolism, echoing metabolic shifts commonly observed in aggressive gastric malignancies. The ablation of HNF4A-dependent transcriptional control may further unleash proliferative and migratory capacities, rendering the knockout cells a compelling system for probing HNF4A’s tumor-suppressive actions in gastrointestinal epithelium. This model also holds relevance for maturity onset diabetes of the young type 1 (MODY1), as HNF4A mutations are causative, and its investigation in extra-hepatic tissues may uncover novel pathophysiological mechanisms.
This HNF4A knockout polyclonal population is suited for a range of experimental applications to interrogate HNF4A biology. Transcriptomic profiling via RNA-seq, combined with RT-qPCR and Western blotting quantification of target gene expression, provides a comprehensive view of HNF4A-dependent transcriptional networks. Immunofluorescence microscopy allows assessment of tight junction integrity and protein localization, while functional assays measuring cell proliferation, migration, and glucose uptake reveal phenotypic consequences of knockout. Chromatin immunoprecipitation (ChIP)-qPCR and reporter assays map HNF4A-DNA interactions and transcriptional activity under defined conditions. Additionally, the cells can be employed in drug screening pipelines to identify compounds that modulate HNF4A signaling, or in studies of intestinal barrier function to examine epithelial permeability changes. For further technical information or custom requirements, please contact Ascent Research.
